Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 22, 2014 08:00 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals Announces Date of Third Quarter 2014 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., Oct. 22, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
October 09, 2014 16:15 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer

CAMBRIDGE, Mass., Oct. 9, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, announced...
October 02, 2014 08:00 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals to Host 2014 R&D Day

CAMBRIDGE, Mass., Oct. 2, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
September 17, 2014 08:30 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals to Webcast Presentation at BioCentury's NewsMakers in the Biotech Industry Conference

CAMBRIDGE, Mass., Sept. 17, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
September 08, 2014 08:30 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals Exercises Option to Acquire Novel Antibodies From AnaptysBio

CAMBRIDGE, Mass., Sept. 8, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
August 28, 2014 09:25 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals Announces Abbreviated New Drug Application for Three-Times-a-Week Generic Copaxone Accepted for Review by FDA

CAMBRIDGE, Mass., Aug. 28, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals (Nasdaq:MNTA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New...
July 31, 2014 08:00 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals Reports Second Quarter 2014 Financial Results

CAMBRIDGE, Mass., July 31, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the second quarter ended June 30, 2014. For the second...
July 30, 2014 16:05 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals to Webcast Presentation at the Canaccord Genuity Growth Conference

CAMBRIDGE, Mass., July 30, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
July 15, 2014 16:05 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals Announces Date of Second Quarter 2014 Financial Results Conference Call and Webcast

CAMBRIDGE, Mass., July 15, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
June 09, 2014 16:05 ET | Source: Momenta Pharmaceuticals

Momenta Pharmaceuticals to Webcast Presentation at the Wells Fargo Healthcare Conference

CAMBRIDGE, Mass., June 9, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...